Soares Holly D, Potter William Z, Pickering Eve, Kuhn Max, Immermann Frederick W, Shera David M, Ferm Mats, Dean Robert A, Simon Adam J, Swenson Frank, Siuciak Judith A, Kaplow June, Thambisetty Madhav, Zagouras Panayiotis, Koroshetz Walter J, Wan Hong I, Trojanowski John Q, Shaw Leslie M
Bristol-Myers Squibb, Wallingford, CT 06492, USA.
Arch Neurol. 2012 Oct;69(10):1310-7. doi: 10.1001/archneurol.2012.1070.
A blood-based test that could be used as a screen for Alzheimer disease (AD) may enable early intervention and better access to treatment.
To apply a multiplex immunoassay panel to identify plasma biomarkers of AD using plasma samples from the Alzheimer's Disease Neuroimaging Initiative cohort.
Cohort study.
The Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project.
Plasma samples at baseline and at 1 year were analyzed from 396 (345 at 1 year) patients with mild cognitive impairment, 112 (97 at 1 year) patients with AD, and 58 (54 at 1 year) healthy control subjects.
Multivariate and univariate statistical analyses were used to examine differences across diagnostic groups and relative to the apolipoprotein E (ApoE) genotype.
Increased levels of eotaxin 3, pancreatic polypeptide, and N-terminal protein B-type brain natriuretic peptide were observed in patients, confirming similar changes reported in cerebrospinal fluid samples of patients with AD and MCI. Increases in tenascin C levels and decreases in IgM and ApoE levels were also observed. All participants with Apo ε3/ε4 or ε4/ε4 alleles showed a distinct biochemical profile characterized by low C-reactive protein and ApoE levels and by high cortisol, interleukin 13, apolipoprotein B, and gamma interferon levels. The use of plasma biomarkers improved specificity in differentiating patients with AD from controls, and ApoE plasma levels were lowest in patients whose mild cognitive impairment had progressed to dementia.
Plasma biomarker results confirm cerebrospinal fluid studies reporting increased levels of pancreatic polypeptide and N-terminal protein B-type brain natriuretic peptide in patients with AD and mild cognitive impairment. Incorporation of plasma biomarkers yielded high sensitivity with improved specificity, supporting their usefulness as a screening tool. The ApoE genotype was associated with a unique biochemical profile irrespective of diagnosis, highlighting the importance of genotype on blood protein profiles.
一种可用于筛查阿尔茨海默病(AD)的血液检测方法或许能够实现早期干预并更好地获得治疗。
应用多重免疫分析方法,利用阿尔茨海默病神经影像学倡议队列中的血浆样本,识别AD的血浆生物标志物。
队列研究。
生物标志物联盟阿尔茨海默病血浆蛋白质组学项目。
分析了396例轻度认知障碍患者(1年后为345例)、112例AD患者(1年后为97例)和58例健康对照者(1年后为54例)基线期和1年后的血浆样本。
采用多变量和单变量统计分析来检验不同诊断组之间以及相对于载脂蛋白E(ApoE)基因型的差异。
在患者中观察到嗜酸性粒细胞趋化蛋白3、胰多肽和N末端B型脑钠肽水平升高,证实了AD和MCI患者脑脊液样本中报告的类似变化。还观察到腱生蛋白C水平升高以及IgM和ApoE水平降低。所有携带Apo ε3/ε4或ε4/ε4等位基因的参与者均表现出独特的生化特征,其特点是C反应蛋白和ApoE水平较低,而皮质醇、白细胞介素13、载脂蛋白B和γ干扰素水平较高。血浆生物标志物的使用提高了区分AD患者与对照者的特异性,并且在轻度认知障碍进展为痴呆的患者中,血浆ApoE水平最低。
血浆生物标志物结果证实了脑脊液研究中关于AD和轻度认知障碍患者胰多肽和N末端B型脑钠肽水平升高的报告。纳入血浆生物标志物具有高敏感性且特异性提高,支持了它们作为筛查工具的实用性。无论诊断如何,ApoE基因型都与独特的生化特征相关,突出了基因型对血液蛋白质谱的重要性。